A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen (CI) treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Although the results from this trial did not meet the primary outcome goals, the findings from exploratory analyses indicated that CI treatment may benefit patients with late-phase dcSSc. This new treatment strategy and preliminary clinical observations in patients with dcSSc need to be corroborated. Postlethwaite AE. Arthritis Rheum. (PubMed)
Oral Type 1 Collagen in Scleroderma. This is a 15-month study to find out if taking type I collagen by mouth will improve diffuse systemic sclerosis (scleroderma). We will randomly assign 168 patients to receive type I collagen from cows or a placebo (inactive treatment) for 12 months. Study dates 2000-2005. ClinicalTrials.gov. This was the original study.
DMSO is an interesting treatment, which is difficult to study in double-blind trials. Read the latest DMSO Scleroderma studies and decide for yourself.
Case Report: Scleredema and diabetic sclerodactyly. A 40-year-old man presented with hardening of the skin of his hands and upper back, which had slowly worsened with time. This patient has improved with aminobenzoate, colchicine, and DMSO gel. PubMed, Dermatol Online J.
Also see: Interstitial Cystitis.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: